FLT3 and leukemia: Multivariate analyses for overall survival, leukemia-free survival, and cumulative incidence of relapse in the overall series, in patients with NPM1 mutations (NPM1mut patients), and in the favorable molecular category (i.e., NPM1 mutation without concomitant FLT3-ITD or CEBPA double mutation), within the cytogenetic intermediate-risk cohort. Age was analyzed with 10-year intervals and white blood cell count at diagnosis using 50 × 109/L increments